Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 293

1.

Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.

Volpe M, Tocci G.

Vasc Health Risk Manag. 2012;8:371-80. doi: 10.2147/VHRM.S28359. Epub 2012 Jun 11. Review.

2.

Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.

da Silva PM.

Clin Drug Investig. 2010;30(9):625-41. doi: 10.2165/11538440-000000000-00000. Review.

PMID:
20626210
3.

Olmesartan/amlodipine: a review of its use in the management of hypertension.

Kreutz R.

Vasc Health Risk Manag. 2011;7:183-92. doi: 10.2147/VHRM.S16852. Epub 2011 Mar 29. Review.

4.

The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.

Schmieder RE.

Clin Exp Hypertens. 2010 Jan;32(1):35-42. doi: 10.3109/10641960902960532. Review.

PMID:
20144071
5.
6.
7.

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A.

Hypertension. 2007 Feb;49(2):276-84. Epub 2006 Dec 11.

8.

Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.

de la Sierra A, Barrios V.

Adv Ther. 2012 May;29(5):401-15. doi: 10.1007/s12325-012-0019-7. Epub 2012 May 17. Review.

PMID:
22610686
9.

Treating essential hypertension. The first choice is usually a thiazide diuretic.

[No authors listed]

Prescrire Int. 2014 Sep;23(152):215-20. Review.

PMID:
25325125
10.

Hypertension management: rationale for triple therapy based on mechanisms of action.

Neutel JM, Smith DH.

Cardiovasc Ther. 2013 Oct;31(5):251-8. doi: 10.1111/1755-5922.12015. Review.

PMID:
23121769
11.

Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.

Tocci G, Paneni F, Passerini J, Volpe M.

Expert Opin Pharmacother. 2012 Dec;13(18):2687-97. doi: 10.1517/14656566.2012.745510. Epub 2012 Nov 21. Review.

PMID:
23170911
12.

Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.

Rump LC, Sellin L.

Expert Opin Pharmacother. 2010 Sep;11(13):2231-42. doi: 10.1517/14656566.2010.510834. Review.

PMID:
20707758
14.

The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis.

Kizilirmak P, Berktas M, Uresin Y, Yildiz OB.

J Clin Hypertens (Greenwich). 2013 Mar;15(3):193-200. doi: 10.1111/jch.12040. Epub 2012 Dec 14. Review.

15.
16.

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.

Duprez D, Ferdinand K, Purkayastha D, Samuel R, Wright R.

Vasc Health Risk Manag. 2011;7:701-8. doi: 10.2147/VHRM.S25743. Epub 2011 Nov 24.

17.

Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.

Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.

Hypertens Res. 2009 Nov;32(11):962-8. doi: 10.1038/hr.2009.133. Epub 2009 Aug 21.

PMID:
19696778
18.

ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients.

Volpe M, de la Sierra A, Kreutz R, Laurent S, Manolis AJ.

High Blood Press Cardiovasc Prev. 2014 Jun;21(2):137-47. doi: 10.1007/s40292-014-0043-6. Epub 2014 Feb 15. Erratum in: High Blood Press Cardiovasc Prev. 2014 Jun;21(2):149-50.

PMID:
24532183
20.

Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study.

Hayashi M, Uchida S, Kawamura T, Kuwahara M, Nangaku M, Iino Y; PROTECT-CKD Study Group..

Clin Exp Nephrol. 2015 Oct;19(5):925-32. doi: 10.1007/s10157-015-1091-5. Epub 2015 Feb 14.

PMID:
25680887

Supplemental Content

Support Center